Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Next Previous
Trial Profile

An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary) ; Pegcetacoplan (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Apellis Pharmaceuticals

Most Recent Events

  • 23 Feb 2024 The trial has been completed in France, according to European Clinical Trials Database record.
  • 12 Dec 2023 Results of an integrated analysis assessing long-term efficacy and safety of pegcetacoplan for PNH treatment from following clinical trials: PEGASUS, PRINCE and their extension trials presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 11 Dec 2023 According to an Apellis Pharmaceuticals media release, post hoc data from PEGASUS and PRINCE studies and the long-term extension study that reinforce the long-term efficacy and safety of EMPAVELI were presented during an oral presentation at the American Society of Hematology (ASH) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top